AKO Life Sciences Uganda Limited (AKOLS™), where innovation meets quality, is humbled and proud to announce the approval of “DERMARLIC Tincture” by the National Drug Authority (NDA). This milestone not only demonstrates our dedication to advancing high-quality, accessible, and sustainable healthcare solutions, however it also highlights the breadth of our collaboration with Mbarara University of Science and Technology (MUST) through the Centre for Innovation and Technology Transfer (CITT) in transforming pharmaceutical research into impactful therapies and outcomes.
Thanks to MUST-CITT for the project’s funding during the first quarter of 2023–2024, which enabled us to ensure the product underwent preclinical investigations and safety and efficacy tests and is presently being manufactured at MUST’s state-of-the-art PHARMBIOTRAC Facility.
A Journey Fueled by Teamwork and Innovation
Our success is a testament to the impact of collaborative innovation. From the initial conceptualization to the rigorous testing phases, every challenge was met with the collective expertise and unwavering determination of our dedicated team. The tireless efforts of our research staff, the technical experts, and the supportive guidance from our mentors have been central to reaching this pivotal moment.
The process to NDA approval was demanding, requiring not only scientific precision but also an intense commitment to excellence. At AKOLS™, we prioritize merging research with practical application. This marks a key milestone in our mission to improve pharmaceutical treatment and healthcare outcomes.
Remarks from the Principal Investigator, Mr. Anyole Arthur Amule
I extend sincere congratulations to every individual involved in the DERMARLIC Tincture Project, with special thanks to Dr. Medard Twinamatsiko (Director of CITT), Dr. Casim Umba Tolo (Director of PHARMBIOTRAC), and Dr. Jonans Tusimiire (Project Mentor), whose mentorship has enabled this approval. Your passion, resilience, and professionalism are the key driving forces behind this achievement. Our collaborative spirit has not only generated a creative environment, but it has also established a standard for what is possible when science and drive come together. The success of DERMARLIC Tincture illustrates our shared commitment to conducting research that will have a long-term impact on healthcare.
Let us embrace this success as a stepping stone to even greater achievements as we eagerly await future inventions that will solidify our position as leaders in pharmaceutical research and development. Here’s to a future full of innovative advancements and better healthcare for all!
Remarks from the Chief Executive Officer, Mr. Kagimu Braize Ben
At AKOLS™, we are proud of our meaningful partnerships that have helped us to achieve significant milestones, particularly with our DERMARLIC Tincture Project. This is one of our nature-inspired innovations, and it has shown tremendous potential across various levels.
Prior to partnering with MUST-CITT, DERMARLIC Tincture was a promising innovation; nevertheless, it lacked the essential support to achieve the rigorous market requirements. However, thanks to the collaboration facilitated by our Executive Director, Mr. Anyole Arthur Amule, the Principal Investigator for the DERMARLIC Tincture Project, we were able to obtain NDA approval, conduct critical preclinical studies to assess the product’s safety and efficacy, and begin the process of registering our intellectual property.
Through this partnership, we are also excited to explore opportunities for conducting clinical trials for DERMARLIC Tincture, which we hope to initiate with MUST-CITT. These trials are a key next step in establishing scientifically proven herbal remedies and will be crucial to the product’s further development.
At AKOLS™, we are committed to nurturing ideas and transforming them into sustainable innovations that benefit society. We understand that without partnerships, accomplishing these objectives would be difficult. We look forward to continuing to form strong, effective collaborations that advance scientific progress and societal well-being.
A Call to Action!
We will not stop here! Our next steps will be to initiate clinical trials, explore further innovations, and engage the community. We invite stakeholders, researchers, and healthcare professionals to join us on this exciting journey to enhance patient outcomes.
Join us as we continue to push the boundaries of pharmaceutical research, making healthcare more accessible and sustainable for everyone.
Tuko Pamoja!